


=> d 11
 L1 HAS NO ANSWERS
 L1 STR



VAR G1=C/S
 REP G2=(0-1) N
 NODE ATTRIBUTES:
 NSPEC IS R AT 14
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

=> s 11 ful
 FULL SEARCH INITIATED 11:20:02 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 116924 TO ITERATE

100.0% PROCESSED 116924 ITERATIONS 240 ANSWERS
 SEARCH TIME: 00.00.10

L3 240 SEA SSS FUL L1

=> fil caplus
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION
 FULL ESTIMATED COST 156.68 156.89

FILE 'CAPLUS' ENTERED AT 11:20:16 ON 23 NOV 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Nov 2004 VOL 141 ISS 22
 FILE LAST UPDATED: 22 Nov 2004 (20041122/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 3 L3

=> d bib abs 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:120841 CAPLUS

DN 140:163856

TI Preparation of benzodioxoles as CB1 receptor modulators for potential therapeutic use against obesity and other disorders

IN Alanine, Alexander; Beleicher, Konrad; Guba, Wolfgang; Haap, Wolfgang; Kuber, Dagmar; Luebbers, Thomas; Plancher, Jean-Marc; Rogers-Evans, Mark; Schneider, Gisbert; Zuegge, Jochen; Roche, Olivier

PA F.Hoffmann-La Roche AG, Switz.

SO PCT Int. Appl., 248 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004013120	A1	20040212	WO 2003-EP7890	20030718
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004142922	A1	20040722	US 2003-626681	20030724
PRAI	EP 2002-16831	A	20020729		
OS	MARPAT 140:163856				
GI					



AB The present invention relates to benzodioxoles (shown as I; variables defined below; e.g. 1-[(2,2-diphenylbenzo[1,3]dioxol-5-yl)sulfonyl]piperidine) and pharmaceutically acceptable salts thereof. The compds. are useful for the treatment and/or prophylaxis of diseases (e.g. obesity (no data)) that are associated with the modulation of CB1 receptors. Cannabinoid CB1 antagonistic activity (IC50) of 12 examples of I is tabulated, e.g. <2 µM for 1-(2,4-dichlorophenyl)-4-(2,2-diphenylbenzo[1,3]dioxole-5-sulfonyl)piperazine. For I: R1 and R2 = unsubstituted Ph, or Ph which is mono, di- or trisubstituted, independently, by hydroxy, lower alkyl, lower alkoxy, perfluoro-lower alkyl, perfluoro-lower alkoxy, alkanoyl, cyano, nitro or halogen; or R1

IN 1,3-Benzodioxole-5-sulfonamide, 2,2-bis(2,4-difluorophenyl)-6-fluoro-N-
[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]- (9CI)
MF C25 H21 F5 N2 O5 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

and R2 together with the C atom to which they are attached form a 10',11'-dihydro-2,5'-(5H)dibenzo[a,d]cycloheptene residue. R3 and R4 = H, halogen, hydroxy, lower alkyl, lower alkoxy, perfluoro-lower alkyl, alkanoyl or cyano; R5 is H, lower alkyl, lower alkylsulfonyl, cycloalkyl lower alkyl or hydroxy-lower alkyl. R6 is Y-R8, lower alkyl, lower alkoxy, hydroxy-lower alkyl, lower alkoxy-lower alkyl, lower alkylaminocarbonyl-lower alkyl, heterocyclyl, cycloalkyl, Ph or Ph lower alkyl; or R6 is H when X is -C(O)- or -SO2-; or R5 and R6 together with the N atom to which they are attached form a 4-7-membered monocyclic or a 8-, 9-, 10-, or 12-membered bicyclic, (un)saturated heterocyclic ring which may optionally contain one or two further heteroatoms = O, N and S, said heterocyclic ring being optionally mono, di- or trisubstituted, independently, by lower alkyl, lower alkoxy, carbonyl, hydroxy lower alkyl, lower alkoxy-lower alkyl, di-lower alkylcarbamoyl, carbamoyl, lower alkylcarbonyl amino, oxo, dioxo, alkanoyl, amino lower alkyl, hydroxy, lower alkoxy, halogen, perfluoro-lower alkyl, cyano, heteroaryl, or by Ph or Ph lower alkyl. R7 is H, halogen, lower alkyl or cyano; R8 is Ph, cycloalkyl, heterocyclyl or heteroaryl; X is a single bond, -CH2-, -C(O)-, -SO2- or -SO2NH-; Y is -CH2-, -C(O)-, -NH- or -SO2-; addnl. details are given in the claims. Methods of preparation are claimed and >250 example preps. are included. For example, 1-[(2,2-diphenylbenzo[1,3]dioxol-5-yl)sulfonyl]piperidine was prepared in 52% yield from 2,2-diphenylbenzo[1,3]dioxole-5-sulfonyl chloride and piperidine in CH2Cl2 in the presence of Et3Pr2N. In another example, 1-[[2-(4-chlorophenyl)-2-(p-tolyl)benzo[1,3]dioxol-5-yl)sulfonyl]-4-(4-fluorophenyl)-1,2,3,6-tetrahydropyridine was prepared by cyclization of 4-chlorophenyl-4-methylphenyldichloromethane with 4-[[4-(4-fluorophenyl)-3,6-dihydro-2H-pyridin-1-yl)sulfonyl]benzene-1,2-diol.


L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1994:473343 CAPLUS
 DN 121:73343
 TI Substituted 1,3-benzodioxole- and 1,3-benzodithiole-2-carboxylates and their tetrazole analogs with potent binding affinity to the angiotensin II AT1 receptor
 AU Rivero, R. A.; Greenlee, W. J.; Chang, R. S. L.
 CS Dep. Explor. Chem., Merck Res. Lab., Rahway, NJ, 07065, USA
 SO Bioorganic & Medicinal Chemistry Letters (1994), 4(5), 747-50
 CODEN: BMCLE8; ISSN: 0960-894X
 DT Journal
 LA English
 GI



AB Inspired by the modest success of a phenoxyphenylacetic acid biphenyl tetrazole replacement, 1,3-benzodioxole-2-carboxylates and 1,3-benzodithiole-2-carboxylates (I, R = O or S) and their resp. tetrazole analogs (II, R = O or S) were investigated as angiotensin II AT1 receptor antagonists. These compds., essentially conformationally restricted analogs of the phenoxyphenylacetic acid series, were quite potent in vitro.


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1993:408811 CAPLUS
 DN 119:8811
 TI Preparation of angiotensin II antagonists incorporating a substituted
 1,3-benzodioxole or 1,3-benzodithiole
 IN Greenlee, William J.; Rivero, Ralph A.
 PA Merck and Co., Inc., USA
 SO U.S., 23 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5187159	A	19930216	US 1991-773070	19911007
	CA 2079770	AA	19930408	CA 1992-2079770	19921002
	EP 543491	A2	19930526	EP 1992-309135	19921007
	EP 543491	A3	19930714		
	R: CH, DE, FR, GB, IT, LI, NL				
	JP 05239033	A2	19930917	JP 1992-293784	19921007
	JP 07005567	B4	19950125		
PRAI	US 1991-773070		19911007		
OS	MARPAT 119:8811				
GI					




AB Title compds. I (R1 = (substituted) C1-6 alkyl, -C2-6 alkenyl, -C2-6 alkynyl, -aryl, -heteroaryl, C1-4 perfluoroalkyl, (C1-4 alkyl)-C3-8 cycloalkyl; A1-A4 = CR4:CR4CR4:CR4, CR4:CR4CR4:N, N:CR4C'R4:CR4, CR4:NCR4:CR4, CR4:CR4N:CR4, etc. wherein R4 = H, (substituted) alkyl, -C2-6 alkenyl, -C1-6 alkynyl, aroyl, C3-7 cycloalkyl, halo, F3C, HO3S, etc.; R6 = H, C1-4 alkyl, (substituted) Ph, -naphthyl; R9, R10 = H, halo, O2N, C1-8 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy; E = bond, O, S(O)n(CH2)s wherein n = 0-2; s = 0-5; y = 0, 1; X = O, S; Z = HO2C, 5-tetrazolyl, F3CO2SNH, 5-tetrazolylcarboxamide, etc.) or a salt thereof, showing antidepressant, enhancement of cognitive function, anxiolytic, antipsychotic, and antihypertensive activity, are prepared Et benzylformate, PC15 and 4-methylcatechol were reacted to Et 5-methyl-2-phenyl-1,3-benzodioxole-2-carboxylate which converted to the 5-bromomethyl derivative reacted with 2-butylbenzimidazole and the product treated with NaOH to give I (R1 = Bu, A1 - A4 = CH:CHCH:CH, E = bond, R6 = R9 = R10 = H, X = O, y = 0, Z = HO2C).

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1994:473343 CAPLUS
 DN 121:73343
 TI Substituted 1,3-benzodioxole- and 1,3-benzodithiole-2-carboxylates and their tetrazole analogs with potent binding affinity to the angiotensin II AT1 receptor
 AU Rivero, R. A.; Greenlee, W. J.; Chang, R. S. L.
 CS Dep. Explor. Chem., Merck Res. Lab., Rahway, NJ, 07065, USA
 SO Bioorganic & Medicinal Chemistry Letters (1994), 4(5), 747-50
 CODEN: BMCLE8; ISSN: 0960-894X
 DT Journal
 LA English
 GI



AB Inspired by the modest success of a phenoxyphenylacetic acid biphenyl tetrazole replacement, 1,3-benzodioxole-2-carboxylates and 1,3-benzodithiole-2-carboxylates (I, R = O or S) and their resp. tetrazole analogs (II, R = O or S) were investigated as angiotensin II AT1 receptor antagonists. These compds., essentially conformationally restricted analogs of the phenoxyphenylacetic acid series, were quite potent in vitro.
 IT **147805-25-2P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and angiotensin II receptor binding activity of)
 RN 147805-25-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 7-methyl-3-[[2-phenyl-2-(1H-tetrazol-5-yl)-1,3-benzodioxol-5-yl]methyl]-2-propyl- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1993:408811 CAPLUS
 DN 119:8811
 TI Preparation of angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
 IN Greenlee, William J.; Rivero, Ralph A.
 PA Merck and Co., Inc., USA
 SO U.S., 23 pp.
 CODEN: USXXAM
 DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5187159	A	19930216	US 1991-773070	19911007
	CA 2079770	AA	19930408	CA 1992-2079770	19921002
	EP 543491	A2	19930526	EP 1992-309135	19921007
	EP 543491	A3	19930714		
	R: CH, DE, FR, GB, IT, LI, NL				
	JP 05239033	A2	19930917	JP 1992-293784	19921007
	JP 07005567	B4	19950125		
PRAI	US 1991-773070		19911007		
OS	MARPAT 119:8811				
GI					



I


AB Title compds. I (R1 = (substituted) C1-6 alkyl, -C2-6 alkenyl, -C2-6 alkynyl, -aryl, -heteroaryl, C1-4 perfluoroalkyl, (C1-4 alkyl)-C3-8 cycloalkyl; A1-A4 = CR4:CR4CR4:CR4, CR4:CR4CR4:N, N:CR4C'R4:CR4, CR4:NCR4:CR4, CR4:CR4N:CR4, etc. wherein R4 = H, (substituted) alkyl, -C2-6 alkenyl, -C1-6 alkynyl, aroyl, C3-7 cycloalkyl, halo, F3C, HO3S, etc.; R6 = H, C1-4 alkyl, (substituted) Ph, -naphthyl; R9, R10 = H, halo, O2N, C1-8 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy; E = bond, O, S(O)n(CH2)s wherein n = 0-2; s = 0-5; y = 0, 1; X = O, S; Z = HO2C, 5-tetrazolyl, F3CO2SNH, 5-tetrazolylcarboxamide, etc.) or a salt thereof, showing antidepressant, enhancement of cognitive function, anxiolytic, antipsydiotic, and antihypertensive activity, are prepared Et benzylformate, PCl5 and 4-methycatechol were reacted to Et 5-methyl-2-phenyl-1,3-benzodioxole-2-carboxylate which converted to the 5-bromomethyl derivative reacted with 2-butylbenzimidazole and the product treated with NaOH to give I (R1 = Bu, A1 - A4 = CH:CHCH:CH, E = bond, R6 = R9 = R10 = H, X = O, y = 0, Z = HO2C).

IT 147805-25-2P 147805-29-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as angiotensin II antagonist)

RN 147805-25-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 7-methyl-3-[[2-phenyl-2-(1H-tetrazol-5-yl)-1,3-benzodioxol-5-yl]methyl]-2-propyl- (9CI) (CA INDEX NAME)



RN 147805-29-6 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 7-methyl-3-[[2-(4-methylphenyl)-2-(1H-tetrazol-5-yl)-1,3-benzodioxol-5-yl]methyl]-2-propyl- (9CI) (CA INDEX NAME)

